SCHEMBL1406253

SCHEMBL1406253

COc1cc(C)c2cc(C(=O)O)c(=O)oc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 1/20 0.59
ALDH1A1 P00352 8/20 0.56
KDM4E B2RXH2 7/20 0.56
CA12 O43570 4/20 0.56
CA2 P00918 4/20 0.56
CA7 P43166 4/20 0.56
CA9 Q16790 4/20 0.56
CA14 Q9ULX7 4/20 0.56
HPGD P15428 4/20 0.56
CA1 P00915 3/20 0.56
CA5A P35218 3/20 0.56
CA5B Q9Y2D0 3/20 0.56
CA3 P07451 3/20 0.56
CA6 P23280 3/20 0.56
CA4 P22748 3/20 0.52
GPR35 Q9HC97 6/20 0.48
HSD17B10 Q99714 1/20 0.47
MAOB P27338 3/20 0.46
GAA P10253 2/20 0.46
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11261487 0.85 SLC16A3 (0.59) SLC16A3ALDH1A1KDM4ECA12CA2
SCHEMBL14326164 0.83 MAOB (0.65) ALDH1A1KDM4ECA12CA2CA7
SCHEMBL11510774 0.81 CA12 (0.54) SLC16A3ALDH1A1KDM4ECA12CA2
SCHEMBL1406487 0.80 NPC1 (0.56) ALDH1A1KDM4EHPGDHSD17B10MAOB
SCHEMBL25142173 0.80 MAOB (0.61) ALDH1A1KDM4ECA12CA2CA7
SCHEMBL1406739 0.80 KDM4E (0.43) SLC16A3ALDH1A1KDM4ECA12CA2
SCHEMBL1406485 0.78 KDM4E (0.47) SLC16A3ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14326441 0.77 CA12 (0.54) SLC16A3ALDH1A1KDM4ECA12CA2
SCHEMBL1406230 0.76 MAPT (0.54) ALDH1A1KDM4EHPGDHSD17B10MAOB
SCHEMBL203997 0.75 SLC16A3 (1.00) SLC16A3ALDH1A1KDM4ECA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295053-B1 Novel 2H-chromen-2-one-3-carboxamides for medical uses INST MATERIA MEDICA CAMS (CN) 2016-10-19 EP disclosed
US-8338401-B2 Coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-12-25 US disclosed
US-8338401-B2 Coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-12-25 US disclosed
EP-2295053-A1 Novel 2H-chromen-2-one-3-carboxamides for medical uses THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2011-03-16 EP disclosed
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-07-06 US disclosed
EP-1570846-A1 THE NOVEL COUMARIN-AMIDE DERIVATIVES AND ITS PREPARATION, SAID DRUG COMPOSITION AND ITS USE THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSR, GLS, INSRR SLC16A3 1156/4885ALDH1A1 1795/4885KDM4E 2436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.